Karen Ruiz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Karen Ruiz has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Felipe de Sousa e Melo
Genentech Research and Early Development, Genentech, Inc., South San Francisco, USA
47 shared publications - Matthew Grimmer
Computational Sciences Center of Excellence, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
47 shared publications - Avi Ashkenazi
Department of Research Oncology, Genentech, Inc., South San Francisco, CA, USA
46 shared publications - Eileen Tan-Aristy
Department of Research Oncology, Genentech, Inc., South San Francisco, California
46 shared publications - Elisia Villemure
Genentech
46 shared publications - Ioanna Oikonomidi
Department of Research Oncology, Genentech, Inc., South San Francisco, California
46 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eadx3959
Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity
Enhancing the specificity of oncogenic pathway inhibition in cancer cells improves both efficacy and tolerability of anticancer therapies. Hyperactivated Wnt signaling is a key driver in cancers such as colorectal cancer and pancreatic ductal adenocarcinoma, but its direct inhibition is limited by severe toxicities due to the importance of Wnt signaling in normal tissues, particularly the gut and bone. To address this challenge, we designed bispecific antibodies that selectively target surface proteins of oncogenic signaling pathways in tumor cells while sparing normal cells. Using single-cell technologies, we identified tumor-specific receptors, including tumor-associated calcium signal transducer 2 (TROP2), which are absent in cells reliant on Wnt signaling. Our TROP2-targeted anti-Frizzled bispecific antibody effectively inhibited Wnt signaling in preclinical models with minimal effect on normal intestinal tissue. Expanding this approach, we developed tumor-targeted, toxicity-sparing bispecific antibodies against fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR). This work establishes a framework for designing targeted therapeutics that minimize cell type–specific toxicities in cancer and other diseases.
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eadx3959
Open AccessTumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicity
Enhancing the specificity of oncogenic pathway inhibition in cancer cells improves both efficacy and tolerability of anticancer therapies. Hyperactivated Wnt signaling is a key driver in cancers such as colorectal cancer and pancreatic ductal adenocarcinoma, but its direct inhibition is limited by severe toxicities due to the importance of Wnt signaling in normal tissues, particularly the gut and bone. To address this challenge, we designed bispecific antibodies that selectively target surface proteins of oncogenic signaling pathways in tumor cells while sparing normal cells. Using single-cell technologies, we identified tumor-specific receptors, including tumor-associated calcium signal transducer 2 (TROP2), which are absent in cells reliant on Wnt signaling. Our TROP2-targeted anti-Frizzled bispecific antibody effectively inhibited Wnt signaling in preclinical models with minimal effect on normal intestinal tissue. Expanding this approach, we developed tumor-targeted, toxicity-sparing bispecific antibodies against fibroblast growth factor receptor 1 (FGFR1) and epidermal growth factor receptor (EGFR). This work establishes a framework for designing targeted therapeutics that minimize cell type–specific toxicities in cancer and other diseases.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Wnt surrogate restores Wnt-pathway activity and growth of PDM-272 organoids in context of ATF6 inhibition
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Wnt surrogate restores Wnt-pathway activity and growth of PDM-272 organoids in context of ATF6 inhibition
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Annotation of CRC organoid mutations
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Annotation of CRC organoid mutations
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Comparison of ER13 and ER16 gene signatures
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Comparison of ER13 and ER16 gene signatures
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption decreases CRC cell seeding capacity
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption decreases CRC cell seeding capacity
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
β-catenin knockdown phenocopies ATF6 silencing
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
β-catenin knockdown phenocopies ATF6 silencing
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption attenuates cell cycle progression and upregulates specific CDK inhibitors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
ATF6 disruption attenuates cell cycle progression and upregulates specific CDK inhibitors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
CRC tumors display elevated expression of ATF6 target genes
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
CRC tumors display elevated expression of ATF6 target genes
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Disruption of ATF6 attenuates growth of multiple CRC cell lines in vitro and in vivo
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway
Disruption of ATF6 attenuates growth of multiple CRC cell lines in vitro and in vivo